Revez, Angli Xue, Xueling Lu, Katri Prna, Harold Snieder, Peter M
First, the next generation of medications, retatrutide, CagriSema, survodutide, and mazdutide, all approach or exceed tirzepatide weight loss results
However, this landscape shifted dramatically in late 2025: the Trump administration negotiated deals with Novo Nordisk and Eli Lilly to offer Wegovy and Zepbound at $245/month for Medicare and Medicaid, and CMS launched the BALANCE Model to begin Medicare Part D coverage of GLP-1s for obesity starting in 2027 (with a bridge demonstration in mid-2026) ( [5] )
The hypothalamicpituitaryadrenal (HPA) axis is a neuroendocrine system that regulates stress responses via hormone feedback loops between the hypothalamus, pituitary gland, and adrenal gland [281]
Weight regain occurred in both treatment and placebo groups over years two through four, though Orlistat users maintained more loss than placebo